Aldesleukin

Summary

Aldesleukin (CHEMBL1201438) is an approved protein (ATC L03AC01); indicated across 112 conditions including metastatic melanoma and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L03AC01
• Indications: 112 conditions
• Clinical trials: 536

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201438
Name	Aldesleukin
Type	Protein
Max phase	4
ATC	L03AC01

Also known as: Aldesleukin, Aldesleukina, Aldesleukine, Human interleukin-2, Ilt-101, ILT-101, Ilt-101 (low dose il-2), Interleukin 2, Interleukin-2, Interleukin-2 aldesleukin, Proleukin, Recombinant interleukin-2 human

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	Interleukin-2 receptor	Agonist

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

112 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
metastatic melanoma	4	MONDO:0005191	EFO:0002617
neoplasm	4	MONDO:0005070	EFO:0000616
melanoma	4	MONDO:0005105	EFO:0000756
cutaneous melanoma	4	MONDO:0005012	EFO:0000389
leukemia	3	MONDO:0005059	EFO:0000565
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222
HIV infectious disease	3	MONDO:0005109	EFO:0000764
renal cell carcinoma	3	MONDO:0005086	EFO:0000681
neuroblastoma	3	MONDO:0005072	EFO:0000621
clear cell renal carcinoma	3	MONDO:0005005	EFO:0000349
neoplasm of mature B-cells	3	MONDO:0004949	EFO:0000096
myelodysplastic syndrome	3	MONDO:0018881	EFO:0000198
acute monocytic leukemia	3	MONDO:0007896	EFO:0000221
acute myelomonocytic leukemia M4	3	MONDO:0018871	EFO:0000223
Burkitt lymphoma	3	MONDO:0007243	EFO:0000309
diffuse large B-cell lymphoma	3	MONDO:0018905	EFO:0000403
lymphoma	3	MONDO:0005062	EFO:0000574
acute megakaryoblastic leukemia	3	MONDO:0018872	EFO:0003025
acute myeloblastic leukemia without maturation	3	MONDO:0005224	EFO:0003027
acute basophilic leukemia	3	MONDO:0019458	EFO:0003029
kidney neoplasm	3	MONDO:0021163	EFO:0003865
breast neoplasm	3	MONDO:0021100	EFO:0003869
head and neck cancer	3	MONDO:0005627	EFO:0006859
chronic myelomonocytic leukemia	3	MONDO:0020311	EFO:1001779
acute erythroid leukemia	3	MONDO:0017858	EFO:0000218
myelodysplastic syndrome with single lineage dysplasia	3	MONDO:0005272	EFO:0003802
myelodysplastic syndrome with excess blasts	3	MONDO:0019454	EFO:0003811
kidney cancer	3	MONDO:0002367	MONDO:0002367
follicular lymphoma	3	MONDO:0018906	MONDO:0018906
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
skin neoplasm	3	MONDO:0002531	MONDO:0002898
dermatomyositis	3	MONDO:0016367	EFO:0000398
systemic lupus erythematosus	3	MONDO:0007915	MONDO:0007915
nephrotic syndrome	2	MONDO:0005377	EFO:0004255
graft versus host disease	2	MONDO:0013730	EFO:0004599
Hodgkins lymphoma	2	MONDO:0004952	EFO:0000183
chronic myeloid leukemia	2	MONDO:0011996	EFO:0000339
Crohn disease	2	MONDO:0005011	EFO:0000384
ovarian carcinoma	2	MONDO:0005140	EFO:0001075
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
ovarian neoplasm	2	MONDO:0021068	EFO:0003893
non-Hodgkin lymphoma	2	MONDO:0018908	EFO:0005952
male breast carcinoma	2	MONDO:0005628	EFO:0006861
inflammatory breast carcinoma	2	MONDO:0006804	EFO:1000984
myositis disease	2	MONDO:0021167	EFO:0000783
Behcet disease	2	MONDO:0007191	EFO:0003780
polymyalgia rheumatica	2	MONDO:0019735	EFO:0008518
fallopian tube carcinoma	2	MONDO:0006206	EFO:1000251
relapsing polychondritis	2	MONDO:0019125	EFO:1001148
B-cell chronic lymphocytic leukemia	2	MONDO:0004948	EFO:0000095
myeloproliferative neoplasm	2	MONDO:0020076	EFO:0002428
central nervous system neoplasm	2	MONDO:0006130	EFO:1000158
peritoneal neoplasm	2	MONDO:0006901	MONDO:0002087
fallopian tube neoplasm	2	MONDO:0021092	MONDO:0002158
ovarian cancer	2	MONDO:0008170	MONDO:0008170
lung neoplasm	2	MONDO:0021117	MONDO:0008903
urothelial carcinoma	2	MONDO:0040679	EFO:0008528
atopic conjunctivitis	2	MONDO:0005642	EFO:0007141
carcinoma	2	MONDO:0004993	EFO:0000313
Alzheimer disease	2	MONDO:0004975	MONDO:0004975
amyotrophic lateral sclerosis	2	MONDO:0004976	MONDO:0004976
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147
ocular melanoma	2	MONDO:0006325	EFO:1000403
uveal melanoma	2	MONDO:0006486	EFO:1000616
alopecia areata	1	MONDO:0005340	EFO:0004192
hepatocellular carcinoma	1	MONDO:0007256	EFO:0000182
mesothelioma	1	MONDO:0005065	EFO:0000588
AIDS	1	MONDO:0012268	EFO:0000765
human papilloma virus infection	1	MONDO:0005161	EFO:0001668
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060
cryoglobulinemia	1	MONDO:0005576	EFO:0005846
Sezary syndrome	1	MONDO:0017844	EFO:1000785
mycosis fungoides	1	MONDO:0009691	EFO:1001051
autoimmune hemolytic anemia	1	MONDO:0020108	EFO:1001264
cutaneous neuroendocrine carcinoma	1	MONDO:0019210	EFO:1001471
macrophage activation syndrome	1	MONDO:0015545	EFO:1001806
sarcoma	1	MONDO:0005089	EFO:0000691
synovial sarcoma	1	MONDO:0010434	EFO:0001376
metastatic neoplasm	1	MONDO:0024883	EFO:0009709
habitual spontaneous abortion	1	MONDO:0006774	EFO:1000954
gliosarcoma	1	MONDO:0016681	EFO:1001465
acute lymphoblastic leukemia	1	MONDO:0004967	EFO:0000220
cytomegalovirus infection	1	MONDO:0005132	EFO:0001062
blast phase chronic myelogenous leukemia, BCR-ABL1 positive	1	MONDO:0006115	EFO:1000131
encephalitis	1	MONDO:0019956	MONDO:0019956
hematopoietic and lymphoid system neoplasm	1	MONDO:0002334	MONDO:0044881
myelodysplastic/myeloproliferative disease	1	MONDO:0020077	MONDO:0020077
cervical carcinoma	1	MONDO:0005131	EFO:0001061
Wiskott-Aldrich syndrome	1	MONDO:0010518	MONDO:0010518
lung adenocarcinoma	1	MONDO:0005061	EFO:0000571
squamous cell lung carcinoma	1	MONDO:0005097	EFO:0000708
myocardial ischemia	1	MONDO:0024644	EFO:1001375
B-cell acute lymphoblastic leukemia	1	MONDO:0004947	EFO:0000094
head and neck squamous cell carcinoma	1	MONDO:0010150	EFO:0000181
glioblastoma	1	MONDO:0018177	EFO:0000519
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618
primary cutaneous T-cell non-Hodgkin lymphoma	1	MONDO:0000607	EFO:0002913
brain cancer	1	MONDO:0001657	MONDO:0001657
colorectal neoplasm	1	MONDO:0005335	MONDO:0005575
glioma	1	MONDO:0021042	MONDO:0100342

12 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 536.

Phase distribution

Phase	Trials
PHASE2	214
PHASE1	148
PHASE1/PHASE2	100
PHASE3	37
Not specified	24
EARLY_PHASE1	7
PHASE4	4
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00006864	PHASE4	COMPLETED	Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
NCT00414765	PHASE4	COMPLETED	Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
NCT02360592	PHASE4	COMPLETED	Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients
NCT04766307	PHASE4	UNKNOWN	A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2
NCT01704716	PHASE3	RECRUITING	High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
NCT05495321	PHASE3	ENROLLING_BY_INVITATION	Interleukin-2 on Active Dermatomyositis
NCT00000949	PHASE3	COMPLETED	A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3
NCT00002649	PHASE3	COMPLETED	Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma
NCT00002702	PHASE3	UNKNOWN	Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx
NCT00002798	PHASE3	COMPLETED	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NCT00002882	PHASE3	COMPLETED	Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
NCT00002945	PHASE3	COMPLETED	High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
NCT00003027	PHASE3	COMPLETED	Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
NCT00003126	PHASE3	COMPLETED	Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
NCT00003414	PHASE3	COMPLETED	Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin’s Disease
NCT00003991	PHASE3	COMPLETED	Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia
NCT00004128	PHASE3	UNKNOWN	Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
NCT00006154	PHASE3	COMPLETED	A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection
NCT00006237	PHASE3	COMPLETED	S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
NCT00006363	PHASE3	COMPLETED	Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
NCT00008203	PHASE3	COMPLETED	Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer
NCT00013611	PHASE3	COMPLETED	Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)
NCT00018941	PHASE3	COMPLETED	Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
NCT00019682	PHASE3	COMPLETED	Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
NCT00026312	PHASE3	COMPLETED	Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
NCT00039234	PHASE3	UNKNOWN	Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
NCT00053807	PHASE3	COMPLETED	Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer
NCT00053820	PHASE3	COMPLETED	Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer
NCT00070187	PHASE2/PHASE3	COMPLETED	Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin’s Lymphoma
NCT00149162	PHASE3	UNKNOWN	Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2
NCT00291369	PHASE3	COMPLETED	Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis
NCT00416429	PHASE3	COMPLETED	Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer
NCT00416871	PHASE3	COMPLETED	Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer
NCT00451984	PHASE3	UNKNOWN	Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2
NCT00502034	PHASE3	COMPLETED	Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.
NCT01041638	PHASE3	COMPLETED	Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma
NCT02278887	PHASE3	COMPLETED	Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
NCT03233828	PHASE3	TERMINATED	Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2
NCT03928275	PHASE2/PHASE3	WITHDRAWN	The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma
NCT04724629	PHASE3	COMPLETED	Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).